Hypermethylated MAL gene – a silent marker of early colon tumorigenesis by Lind, Guro E et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Research
Hypermethylated MAL gene – a silent marker of early colon 
tumorigenesis
Guro E Lind1,2, Terje Ahlquist1,2, Matthias Kolberg1,2, Marianne Berg1,2, 
Mette Eknæs1,2, Miguel A Alonso3, Anne Kallioniemi4, Gunn I Meling5,6, 
Rolf I Skotheim1,2, Torleiv O Rognum7, Espen Thiis-Evensen8 and 
Ragnhild A Lothe*1,2
Address: 1Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, Rikshospitalet University Hospital, 
Oslo, Norway, 2Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway, 3Centro de Biología Molecular Severo Ochoa, Consejo Superior 
de Investigaciones Científicas y Universidad Autónoma de Madrid, Madrid, Spain, 4Laboratory of Cancer Genetics, Institute of Medical 
Technology, Tampere University Hospital and University of Tampere, Tampere, Finland, 5Department of Urology, Akershus University Hospital, 
Lørenskog, Norway, 6Faculty of Medicine, University of Oslo, Oslo, Norway, 7Institute of Forensic Medicine, Rikshospitalet University Hospital, 
Oslo, Norway and 8Medical Department, Rikshospitalet University Hospital, Oslo, Norway
Email: Guro E Lind - Guro.Elisabeth.Lind@rr-research.no; Terje Ahlquist - terje.c.ahlquist@rr-research.no; 
Matthias Kolberg - matthias.kolberg@rr-research.no; Marianne Berg - marianne.berg@rr-research.no; Mette Eknæs - metteek@rr-research.no; 
Miguel A Alonso - maalonso@cbm.uam.es; Anne Kallioniemi - anne.kallioniemi@uta.fi; Gunn I Meling - gi@meling.net; 
Rolf I Skotheim - rolf.i.skotheim@rr-research.no; Torleiv O Rognum - t.o.rognum@medisin.uio.no; Espen Thiis-Evensen - Espen.Thiis-
Evensen@rikshospitalet.no; Ragnhild A Lothe* - rlothe@rr-research.no
* Corresponding author    
Abstract
Background: Tumor-derived aberrantly methylated DNA might serve as diagnostic biomarkers for cancer, but so far, few such
markers have been identified. The aim of the present study was to investigate the potential of the MAL (T-cell differentiation
protein) gene as an early epigenetic diagnostic marker for colorectal tumors.
Methods: Using methylation-specific polymerase chain reaction (MSP) the promoter methylation status of MAL was analyzed
in 218 samples, including normal mucosa (n = 44), colorectal adenomas (n = 63), carcinomas (n = 65), and various cancer cell
lines (n = 46). Direct bisulphite sequencing was performed to confirm the MSP results. MAL gene expression was investigated
with real time quantitative analyses before and after epigenetic drug treatment. Immunohistochemical analysis of MAL was done
using normal colon mucosa samples (n = 5) and a tissue microarray with 292 colorectal tumors.
Results: Bisulphite sequencing revealed that the methylation was unequally distributed within the MAL promoter and by MSP
analysis a region close to the transcription start point was shown to be hypermethylated in the majority of colorectal carcinomas
(49/61, 80%) as well as in adenomas (45/63, 71%). In contrast, only a minority of the normal mucosa samples displayed
hypermethylation (1/23, 4%). The hypermethylation of MAL was significantly associated with reduced or lost gene expression in
in vitro models. Furthermore, removal of the methylation re-induced gene expression in colon cancer cell lines. Finally, MAL
protein was expressed in epithelial cells of normal colon mucosa, but not in the malignant cells of the same type.
Conclusion: Promoter hypermethylation of MAL was present in the vast majority of benign and malignant colorectal tumors,
and only rarely in normal mucosa, which makes it suitable as a diagnostic marker for early colorectal tumorigenesis.
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Background
Epigenetic changes – non-sequence-based alterations that
are inherited through cell division [1] – are frequently
seen in human cancers, and likewise as genetic alterations
they may lead to disruption of gene function. In colorectal
cancer, several tumour suppressor genes have been identi-
fied to be epigenetically inactivated by CpG island pro-
moter hypermethylation, including the DNA mismatch
repair gene MLH1 [2-4], the gatekeeper APC [5], and the
cell cycle inhibitor CDKN2A  [6], to mention some. In
addition to contributing to, or accompanying, the step-
wise development of malignant colorectal carcinomas
from benign adenomas, aberrant DNA methylation holds
great promises for cancer diagnostics [7]. Based on the
ubiquity of aberrant promoter methylation and the ability
to detect this methylated DNA in body fluids, such as
blood, the presence of this altered DNA may represent
potential diagnostic biomarkers for cancer. For non-inva-
sive detection of colorectal tumours, stool is the obvious
source of DNA for such investigations and several studies
have identified cancer-derived aberrant DNA hypermeth-
ylation using this approach [8-10]. However, the sensitiv-
ity and specificity of these tests are still suboptimal and
would benefit from incorporating additional biomarkers.
We recently published a list of promising novel target
genes for hypermethylation in colorectal tumours [11].
Among these was the MAL (T-cell differentiation protein)
gene, and we then communicated that the CpG rich pro-
moter of MAL  seemed to be hypermethylated in the
majority of colorectal tumours [12].
The MAL gene, which was initially isolated and cloned in
1987, maps to chromosome band 2cen-q13, encodes a 17
kDa integral membrane protein, and contains a CpG
island [13,14]. Originally, expression of MAL was found
in intermediate and late stages of T-cell differentiation,
and MAL was suggested to play a role in membrane signal-
ling [15]. In recent years, MAL has also been shown to
play a role in apical transport, which is a polarized trans-
port of lipids and proteins to the apical (external facing)
membrane in certain cell types [16]. Such polarized trans-
port is essential for the proper functioning of epithelial
cells, and the neoplastic transformation process is fre-
quently associated with loss of this polarized phenotype
[16]. Finally, MAL has been shown to possess tumour sup-
pressor capabilities by suppressing motility, invasion, and
tumorigenicity and enhance apoptosis in oesophageal
cancer [17].
In the present study, we have compared the promoter
methylation status of MAL  in a large series of normal
colorectal mucosa samples, with those of benign and
malignant colorectal tumours. Furthermore, RNA and/or
protein expression levels of MAL were determined in in
vivo tumours as well as in in vitro models, the latter also
including various cancer types. The findings were used to
decide whether or not methylated MAL is suitable as a
diagnostic marker for early colorectal tumorigenesis.
Methods
Patients and cell lines
DNA from 218 fresh-frozen samples was subjected to
methylation analysis, including 65 colorectal carcinomas
(36 micro satellite stable; MSS, and 29 with micro satellite
instability; MSI) from 64 patients, 63 adenomas, median
size 8 mm, range 5–50 mm (61 MSS and 2 MSI) from 52
patients, 21 normal mucosa samples from 21 colorectal
cancer patients (taken from distant sites from the primary
carcinoma), and another 23 normal colorectal mucosa
samples from 22 cancer-free individuals, along with 20
colon cancer cell lines (11 MSS and 9 MSI), and 26 cancer
cell lines from various tissues (breast, kidney, ovary, pan-
creas, prostate, and uterus; Table 1). The mean age at diag-
nosis was 70 years (range 33 to 92) for patients with
carcinoma, 67 years (range 62 to 72) for persons with ade-
nomas, 64 years (ranging from 24 to 89) for the first
group of normal mucosa donors, and 54 years (ranging
from 33 to 86) for the second group of normal mucosa
donors. The colorectal carcinomas and normal samples
from cancer patients were obtained from an unselected
prospective series collected from seven hospitals located
in the South-East region of Norway [18]. The adenomas
were obtained from individuals attending a population
based sigmoidoscopic screening program for colorectal
cancer [19]. The normal mucosa samples from cancer-free
individuals were obtained from deceased persons, and the
majority of the total set of normal samples (27/44) con-
sisted of mucosa only, whereas the remaining samples
were taken from the bowel wall. Additional clinico-path-
ological data for the current tumour series include gender
and tumour location, as well as polyp size and total
number of polyps per individual for the adenoma series.
All samples were retrieved from approved research
biobanks and are part of research projects approved
according to national guidelines (Biobank; registered at
the Norwegian Institute of Public Health. Projects:
Regional Ethics Committee and National Data Inspector-
ate).
Two colon cancer cell lines, HCT15 and HT29, were sub-
jected to treatment with the demethylating drug 5-aza-
2'deoxycytidine (1 μM for 72 h), the histone deactetylase
inhibitor trichostatin A (0.5 μM for 12 h) and a combina-
tion of both (1 μM 5-aza-2'deoxycytidine for 72 h, 0.5 μM
trichostatin A added the last 12 h).Journal of Translational Medicine 2008, 6:13 http://www.translational-medicine.com/content/6/1/13
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Table 1: Promoter methylation status of MAL in cell lines of various tissues.
Cell line Tissue Promoter methylation status Methylation frequency
BT-20 Breast M 57%
BT-474 Breast U/M
Hs 578T Breast U
SK-BR-3 Breast U
T-47D Breast U/M
ZR-75-1 Breast U
ZR-75-38 Breast M
Co115 Colon M 95%
HCT15 Colon M
HCT116 Colon M
LoVo Colon M
LS174T Colon M
RKO Colon M
SW48 Colon M
TC7 Colon M
TC71 Colon M
ALA Colon M
Colo320 Colon M
EB Colon M
FRI Colon U/M
HT29 Colon M
IS1 Colon M
IS2 Colon M
IS3 Colon M
LS1034 Colon M
SW480 Colon M
V9P Colon U
ACHN Kidney U 50%
Caki-1 Kidney U
Caki-2 Kidney M
786-O Kidney U/M
ES-2 Ovary U/M 50%
OV-90 Ovary U/M
Ovcar-3 Ovary U
SK-OV-3 Ovary U
AsPC-1 Pancreas M 67%
BxPC-3 Pancreas U
CFPAC-1 Pancreas U
HPAF-II Pancreas M
PaCa-2 Pancreas M
Panc-1 Pancreas U/M
LNCaP Prostate U 0%
AN3 CA Uterus U/M 75%
HEC-1-A Uterus M
KLE Uterus U
RL95-2 Uterus M
The promoter methylation status of the individual cell lines was assessed by methylation-specific polymerase chain reaction (MSP). The methylation 
frequency reflects the number of methylated (M and U/M) samples from each tissue. Abbreviations: U, unmethylated; M, methylated.Journal of Translational Medicine 2008, 6:13 http://www.translational-medicine.com/content/6/1/13
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Bisulphite treatment and methylation-specific polymerase 
chain reaction (MSP)
DNA from primary tumours and normal mucosa samples
was bisulphite treated as previously described [11,20],
whereas DNA from colon cancer cell lines was bisulphite
treated using the EpiTect bisulphite kit (Qiagen Inc.,
Valencia, CA, USA). The promoter methylation status of
MAL  was analyzed by methylation-specific polymerase
chain reaction (MSP) [21], using the HotStarTaq DNA
polymerase (Qiagen). All results were confirmed with a
second independent round of MSP. Human placental
DNA (Sigma Chemical Co, St. Louis, MO, USA) treated in
vitro with Sss1 methyltransferase (New England Biolabs
Inc., Beverly, MA, USA) was used as a positive control for
the methylated MSP reaction, whereas DNA from normal
lymphocytes was used as a positive control for unmethyl-
ated alleles. Water was used as a negative control in both
reactions. The primers were designed with MethPrimer
[22] and their sequences are listed in Table 2, along with
the product fragment lengths and primer locations.
Bisulphite sequencing
All colon cancer cell lines (n = 20) were subjected to direct
bisulphite sequencing of the MAL  promoter [23]. Two
fragments were amplified: fragment A, covering bases -68
to 168 relative to the transcription start point (overlap-
ping with our MSP product), and fragment B covering
bases -427 to -23. Fragment A covered altogether 24 CpG
sites and was amplified using the HotStarTaq DNA
polymerase and 35 PCR cycles. Fragment B covered alto-
gether 32 CpG sites and was amplified using the same
polymerase and 36 PCR cycles. The primer sequences are
listed in Table 2. Excess primer and nucleotides were
removed by ExoSAP-IT treatment following the protocol
of the manufacturer (GE Healthcare, USB Corporation,
Ohio, USA). The purified products were subsequently
sequenced using the dGTP BigDye Terminator Cycle
Sequencing Ready Reaction kit (Applied Biosystems, Fos-
ter City, CA, USA) in an AB Prism 3730 sequencer
(Applied Biosystems). The approximate amount of
methyl cytosine of each CpG site was calculated by com-
paring the peak height of the cytosine signal with the sum
of the cytosine and thymine peak height signals, as previ-
ously described [24]. CpG sites with ratios ranging from 0
– 0.20 were classified as unmethylated, CpG sites within
the range 0.21 – 0.80 were classified as partially methyl-
ated, and CpG sites ranging from 0.81 – 1.0 were classified
as hypermethylated.
cDNA preparation and real-time quantitative gene 
expression
Total RNA was extracted from cell lines (n = 46), tumours
(n = 16), and normal tissue (n = 3) using Trizol (Invitro-
gen, Carlsbad, CA, USA) and the RNA concentration was
determined using ND-1000 Nanodrop (NanoDrop Tech-
nologies, Wilmington, DE, USA). For each sample, total
RNA was converted to cDNA using a High-Capacity cDNA
Archive kit (Applied Biosystems), including random
primers. MAL (Hs00242749_m1 and Hs00360838_m1)
and the endogenous controls ACTB (Hs99999903_m1)
and GUSB (Hs99999908_m1) were amplified separately
in 96 well fast plates following the recommended proto-
col (Applied Biosystems), and the real time quantitative
gene expression was measured by the 7900 HT Sequence
Detection System (Applied Biosystems). All samples were
analyzed in triplicate, and the median value was used for
data analysis. The human universal reference RNA (con-
taining a mixture of RNA from ten different cell lines;
Stratagene) was used to generate a standard curve, and the
resulting quantitative expression levels of MAL were nor-
malized against the mean value of the two endogenous
controls.
Tissue microarray
For in situ detection of protein expression in colorectal
cancers, a tissue microarray (TMA) was constructed, based
on the technology previously described [25]. Embedded
in the TMA are 292 cylindrical tissue cores (0.6 mm in
diameter) from ethanol-fixed and paraffin embedded
tumour samples derived from 281 individuals. Samples
from the same patient series has been examined for vari-
ous biological variables and clinical end-points [18,26-
28]. In addition, the array contains normal tissues from
kidney, liver, spleen, and heart as controls. Ethanol-fixed
Table 2: PCR primers used for MSP and bisulphite sequencing.
Primer set Sense primer Antisense primer Frg. Size, bp An. Temp Fragment location*
MAL MSP-M TTCGGGTTTTTTTGTTTTTAATT
C
GAAAACCATAACGACGTACTAA
CGT
139 56 -71 to 68
MAL MSP-U TTTTGGGTTTTTTTGTTTTTAAT
TT
ACAAAAACCATAACAACATACT
AACATC
142 56 -72 to 70
MAL BS_A GGGTTTTTTTGTTTTTAATT ACCAAAAACCACTCACAAACTC 236 53 -68 to 168
MAL BS_B GGAAAAATGAAGGAGATTTAA
ATTT
AATAACCTAAACRCCCCC 404 50 -427 to -23
Abbreviations: MSP, methylation-specific polymerase chain reaction; BS, bisulphite sequencing; M, methylated-specific primers; U, unmethylated-
specific primers; Frg. Size, fragment size; An. Temp, annealing temperature (in degrees celsius). *Fragment location lists the start and end point (in 
base pairs) of each fragment relative to the transcription start point provided by NCBI (RefSeq ID NM_002371).Journal of Translational Medicine 2008, 6:13 http://www.translational-medicine.com/content/6/1/13
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normal colon tissues from four persons with no known
history of colorectal cancer were obtained separately.
Immunohistochemical in situ protein expression analysis
Five μm thick sections of the TMA blocks were transferred
onto glass slides for immunohistochemical analyses. The
sections were deparaffinized in a xylene bath for 10 min-
utes and rehydrated via a series of graded ethanol baths.
Heat-induced epitope retrieval was performed by heating
in a microwave oven at full effect (850 W) for 5 minutes
followed by 15 minutes at 100 W immersed in 10 mM cit-
rate buffer at pH 6.0 containing 0.05% Tween-20. After
cooling to room temperature, the immunohistochemical
staining was performed according to the protocol of the
DAKO Envision+™ K5007 kit (Dako, Glostrup, Den-
mark). The primary antibody, mouse clone 6D9 anti-MAL
[29], was used at a dilution of 1:5000, which allowed for
staining of kidney tubuli as positive control, while the
heart muscle tissue remained unstained as negative con-
trol [30]. The slides were counterstained with haematoxy-
lin for 2 minutes and then dehydrated in increasing grades
of ethanol and finally in xylene. Results from the immu-
nohistochemistry were obtained by independent scoring
by one of the authors and a reference pathologist.
Statistics
All P values were derived from two tailed statistical tests
using the SPSS 13.0 software (SPSS, Chicago, IL, USA).
Fisher's exact test was used to analyze 2 × 2 contingency
tables. A 2 × 3 table and Chi-square test was used to ana-
lyze the potential association between quantitative gene
expression of MAL  and promoter methylation status.
Samples were divided into two categories according to
their gene expression levels: low expression included sam-
ples with gene expression equal to, or lower than, the
median value across all cell lines or all tumours, high
expression included samples with gene expression higher
that the median. The methylation status was divided into
three categories: unmethylated, partial methylation, and
hypermethylated.
Results
Promoter methylation status of MAL in tissues and cell 
lines
The promoter methylation status of MAL was analyzed
with MSP (Figure 1). One of 23 (4%) normal mucosa
samples from non-cancerous donors and two of 21 (10%)
normal mucosa samples taken in distance from the pri-
mary tumour were methylated but displayed only low-
intensity band compared with the positive control after
gel electrophoresis. Forty-five of 63 (71%) adenomas and
49/61 (80%) carcinomas showed promoter hypermethyl-
ation. Nineteen of twenty colon cancer cell lines (95%),
and 15/26 (58%) cancer cell lines from various tissues
(breast, kidney, ovary, pancreas, prostate, and uterus)
were hypermethylated (Table 1 lists tissue-specific fre-
quencies).
The hypermethylation frequency found in normal sam-
ples was significantly lower than in adenomas (P  <
0.0001) and carcinomas (P < 0.0001). Hypermethylation
of the MAL promoter was not associated with MSI status,
gender, or age in neither malignant nor benign tumours.
Among carcinomas, tumours with distal location in the
bowel (left side and rectum) were more frequently hyper-
methylated than were tumours with proximal location,
although not statistically significant (P = 0.088). Among
adenomas, no significant association could be found
between promoter methylation status of MAL and polyp
size or number.
Bisulphite sequencing verification of the promoter 
methylation status of MAL
Two overlapping fragments of the MAL promoter were
bisulphite sequenced in 20 colon cancer cell lines. The
results are summarized in Figure 2, and representative raw
data can be seen in Figure 3. A good association was seen
between the methylation status, as assessed by MSP, and
the bisulphite sequences of the overlapping fragment A.
However, in fragment B there was poor association with
the MSP data. For this fragment, which is located farther
upstream relative to the transcription start point, several
consecutive CpG sites were frequently unmethylated and/
or partially methylated. This held true also in cell lines
shown to be heavily methylated around the transcription
start point (fragment A; Figure 2).
Methylation status of the MAL promoter in normal colon  mucosa samples and colorectal carcinomas Figure 1
Methylation status of the MAL promoter in normal 
colon mucosa samples and colorectal carcinomas. 
Representative results from methylation-specific polymerase 
chain reaction are shown. A visible PCR product in lanes U 
indicates the presence of unmethylated alleles whereas a 
PCR product in lanes M indicates the presence of methylated 
alleles. N, normal mucosa; C, carcinoma; Pos, positive con-
trol (unmethylated reaction: DNA from normal blood, meth-
ylated reaction: in vitro methylated DNA); Neg, negative 
control (containing water as template); U, lane for unmethyl-
ated MSP product; M, lane for methylated MSP product.Journal of Translational Medicine 2008, 6:13 http://www.translational-medicine.com/content/6/1/13
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Real-time quantitative gene expression
The level of MAL mRNA expression in cell lines (n = 46),
primary colorectal carcinomas (n = 16), and normal
mucosa (n = 3) was assessed by quantitative real time
PCR. There was a strong association between MAL pro-
moter hypermethylation and reduced or lost gene expres-
sion among cell lines (P = 0.041; Figure 4). Furthermore,
the gene expression of MAL was up-regulated in colon
cancer cell lines after promoter demethylation induced by
the combined treatment 5-aza-2'-deoxycytidine and tri-
chostatin A (Figure 5). Treatment with the deacetylase
inhibitor trichostatin A alone did not increase MAL
expression, whereas treatment with the DNA demethylat-
ing 5-aza-2'-deoxycytidine led to high expression in HT29
cells, but more moderate levels in HCT15 cells (Figure 5).
Among primary colorectal carcinomas, those harbouring
promoter hypermethylation of MAL (n = 13) expressed
somewhat lower levels of MAL mRNA compared with the
unmethylated tumours (n = 3), although not statistically
significant (Figure 4).
MAL protein expression is lost in colorectal carcinomas
To evaluate the immunohistochemistry analyses of MAL,
kidney and heart muscle tissues were included as positive
and negative controls, respectively (Figure 6A–B) [30].
From the 231 scorable colorectal tissue cores, i.e. those
containing malignant colorectal epithelial tissue, 198
were negative for MAL staining (Figure 6C–D). Twenty-
nine of these had positive staining in non-epithelial tissue
components within the same tissue cores, mainly in neu-
rons and blood vessels (not shown). In comparison, all
the sections of normal colon tissue contained positive
staining for MAL in the epithelial cells (Figure 6E–F).
Discussion
In the present study, we have demonstrated that a
sequence within the MAL promoter close to the transcrip-
tion start is hypermethylated in the vast majority of malig-
nant, as well as in benign colorectal tumours, in contrast
to normal colon mucosa samples which are unmethyl-
ated, and we contend that MAL remains a promising diag-
nostic biomarker for early colorectal tumorigenesis [12].
The adenomas and carcinomas analyzed in the present
study are from unselected clinical series and are therefore
representative for the average risk population. However,
the equal distribution between MSI and MSS carcinomas
in the present study is not representative for a consecutive
series.
Hypermethylation of MAL has, by quantitative methyla-
tion-specific polymerase chain reaction (MSP), previously
been shown by others to be present only in a small frac-
tion (6%, 2/34) of colon carcinomas [31], even though
the expression of MAL was reported to be reduced/lost in
the majority of colorectal tumours [11,17,31]. In contrast,
we report here a significantly higher methylation fre-
Site specific methylation within the MAL promoter Figure 2
Site specific methylation within the MAL promoter. Bisulphite sequencing of the MAL promoter verifies methylation 
status assessed by methylation-specific polymerase chain reaction. The upper part of the figure is a schematic presentation of 
the CpG sites successfully amplified by the two analyzed bisulphite sequencing fragments, A (-68 to +168; to the right) and B (-
427 to -85; to the left). The transcription start site is represented by +1 and the vertical bars indicate the location of individual 
CpG sites. The two arrows indicate the location of the MSP primers in the present study and a previously published study ana-
lyzing promoter methylation of MAL [31]. For the lower part of the figure, filled circles represent methylated CpGs; open cir-
cles represent unmethylated CpGs; and open circles with a slash represent partially methylated sites (the presence of 
approximately 20–80% cytosine, in addition to thymine). The column of U, M and U/M at the right side of this lower part lists 
the methylation status of the respective cell lines as assessed by us using MSP analyses. Abbreviations: MSP, methylation-spe-
cific PCR; s, sense; as, antisense; U, unmethylated; M, methylated; U/M, presence of both unmethylated and methylated band.Journal of Translational Medicine 2008, 6:13 http://www.translational-medicine.com/content/6/1/13
Page 7 of 11
(page number not for citation purposes)
quency of MAL in both benign and malignant colorectal
tumours (71% in adenomas and 80% in carcinomas). The
discrepancy in methylation frequencies between the
present report and the previous study by Mori and co-
workers [31] is probably a consequence of study design.
From direct bisulphite sequencing of colon cancer cell
lines, we have now shown that the DNA methylation of
MAL is unequally distributed within the CpG island of its
promoter (Figure 2). CpG islands often span more than
one kilobase of the gene promoter, and the methylation
status within this region is sometimes mistakenly
assumed to be equally distributed. This is exemplified by
the MLH1 gene in which hypermethylation of a limited
number of CpG sites approximately 200 base pairs
upstream of the transcription start point invariably corre-
lates with the lack of gene expression, while other sites do
not [32,33]. Since the results of an MSP analysis rely on
the match or mismatch of the unmethylated and methyl-
ated primer sequences to bisulphite treated DNA, one
should ensure that the primers anneal to relevant CpG
sites in the gene promoter. In the present study, we
designed the MSP primers close to the transcription start
point of the gene (-72 to +70) and found, by bisulphite
sequencing, concordance between the overall methyla-
tion status of MAL as assessed by MSP and the methyla-
tion status of the individual CpG sites covered by our MSP
primer set (Figure 2). This part of the CpG island was
hypermethylated in the majority of colon cancer cell lines
(95%). We also found that these cell lines, as well as those
of other tissues, showed loss of MAL RNA expression from
quantitative real time analyses, and that removal of DNA
hypermethylation by the combined treatment of 5-aza-2'-
deoxycytidine and Trichostatin A re-induced the expres-
sion of MAL in colon cancer cell lines (Figure 5). Further-
more, by analyzing a large series of clinically
representative samples by protein immunohistochemistry
we confirmed that the expression of MAL was lost in
malignant colorectal epithelial cells as compared to nor-
mal mucosa.
We have further analyzed the same region of the MAL pro-
moter as Mori et al., which is located -206 to -126 base
pairs upstream of the transcription start point [31]. By
direct bisulphite sequencing, we showed that only a
minority of the CpG sites covered by the Mori antisense
primer were methylated in the 19 colon cancer cell lines
The "bisulphite sequence" of the MAL promoter Figure 3
The "bisulphite sequence" of the MAL promoter. Representative bisulphite sequencing electropherograms of the MAL 
promoter in colon cancer cell lines. A subsection of the bisulphite sequence electropherogram, covering CpG sites +11 to +15 
relative to transcription start. Cytosines in CpG sites are indicated by a black arrow, whereas cytosines that have been con-
verted to thymines are underlined in red. The MAL promoter sequencing electropherograms illustrated here, are from the 
unmethylated V9P cell line and the hypermethylated ALA and HCT116.Journal of Translational Medicine 2008, 6:13 http://www.translational-medicine.com/content/6/1/13
Page 8 of 11
(page number not for citation purposes)
that were heavily methylated around the transcription
start point (Figure 2). We therefore conclude that the very
low (six percent) methylation frequency initially reported
for MAL in colon carcinomas [31] is most likely a conse-
quence of the primer design and choice of CpG sites to be
examined.
Inactivating hypermethylation of the MAL  promoter
might be prevalent also in other cancer types where low
expression of MAL has been shown not to correlate with
allelic loss or somatic mutations in the MAL gene [34]. In
the present study, hypermethylated MAL was found in
cancer cell lines from breast, kidney, ovary, and uterus.
The present analyses of cancer cell lines from seven tissues
indicate that the hypermethylation of a limited area in the
proximity of the transcription start point of MAL is associ-
ated with reduced or lost gene expression. However,
among colorectal carcinomas and cell lines, MAL protein
and gene expression seemed to be lost or reduced in all
samples, including the minority with unmethylated MAL
promoters. This underlines that loss of the MAL protein
might have an important function in colorectal tumori-
genesis and we hypothesize that early during colorectal
neoplasia the gene is turned off by epigenetic mechanisms
other than DNA methylation. The DNA methylation is
subsequently recruited to the MAL promoter to "seal" the
unexpressed state. Hence, it needs to be established
MAL expression in cancer cell lines and colorectal carcinomas Figure 4
MAL expression in cancer cell lines and colorectal carcinomas. Promoter hypermethylation of MAL was associated 
with reduced or lost gene expression in in vitro models. The quantitative gene expression level of MAL is displayed as a ratio 
between the average of two MAL assays (detecting various splice variants) and the average of the two endogenous controls, 
GUSB and ACTB. The value has been multiplied by a factor of 1000. Below each sample the respective methylation status is 
shown, as assessed by methylation-specific polymerase chain reaction. Filled circles represent promoter hypermethylation of 
MAL, open circles represent unmethylated MAL, and open circles with a slash represent the presence of both unmethylated and 
methylated alleles. Colorectal carcinomas are divided in an unmethylated group (n = 3) and a hypermethylated group (n = 13), 
and the median expression is displayed here. The tissue of origin for the individual cell lines can be found in table 1.Journal of Translational Medicine 2008, 6:13 http://www.translational-medicine.com/content/6/1/13
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whether MAL promoter hypermethylation is a cause or a
consequence of the observed loss of gene expression in
colorectal tumors. This is interesting from a biological –
but not necessarily a diagnostic – perspective. The distinc-
tion between the two is supported by the fact that one of
the most promising diagnostic biomarkers for colorectal
cancer reported so far, DNA hypermethylation of the
vimentin (VIM) gene, is not expected to alter the gene
expression, nor to confer a selective advantage upon can-
cer cells in the colon, considering the lack of VIM expres-
sion by normal colonic epithelial cells [9].
A sensitive non-invasive screening approach for colorectal
cancer could markedly improve the clinical outcome for
the patient. Such a diagnostic test could in principle meas-
ure the status of a single biomarker, although multiple
markers are probably needed to achieve sufficient sensitiv-
ity and specificity. Several studies have successfully
detected such tumour-specific products in the faeces, and
most experience has been with mutant genetic markers,
including APC, KRAS, TP53, and BAT-26 [35]. However,
one of the most promising faecal DNA tests so far con-
sisted of a combination of a genetic DNA integrity assay
and an epigenetic VIM  methylation assay, resulting in
88% sensitivity and 82% specificity [36]. This panel might
be further improved by implementing MAL  and/or, as
suggested by others, the SFRP2 marker, which has an inde-
pendent sensitivity and specificity of 77% in faecal DNA
[8].
Hypermethylation of the MAL promoter represents, to the
best of our knowledge, the most frequently hypermethyl-
ated gene among pre-malignant colorectal lesions, accom-
panied by low methylation frequencies in normal colon
mucosa. The presence of such epigenetic changes in pre-
malignant tissues might also have implications for cancer
chemoprevention. By inhibiting or reversing these epige-
netic alterations, the progression to a malignant pheno-
type might be prevented [37]. However, for the purpose of
cancer risk assessment, MAL methylation status should be
used in combination with other markers to recognize high
risk adenomas.
Conclusion
Promoter hypermethylation of MAL remains one of the
most promising diagnostic biomarkers for early detection
of colorectal tumours, and, together with other biomark-
ers, it merits further investigation with the purpose of
developing a diagnostic marker panel with the necessary
sensitivity and specificity to discover colorectal neoplasia
and perform a risk assessment.
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